First-in-Human Experience With Ultra-Low Temperature Cryoablation for Monomorphic Ventricular Tachycardia
Jazyk angličtina Země Spojené státy americké Médium print-electronic
Typ dokumentu časopisecké články, přehledy, práce podpořená grantem
PubMed
36752466
DOI
10.1016/j.jacep.2022.11.017
PII: S2405-500X(22)01049-0
Knihovny.cz E-zdroje
- Klíčová slova
- ultra-low temperature cryoablation, ventricular tachycardia ablation,
- MeSH
- endokard MeSH
- komorová tachykardie * MeSH
- kryochirurgie * škodlivé účinky MeSH
- lidé MeSH
- srdeční komory MeSH
- teplota MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- přehledy MeSH
Ultra-low temperature cryoablation (ULTC) using near-critical nitrogen (-196ºC) has been shown to produce durable, contiguous, transmural lesions in ventricles of animal models. This report summarizes acute experience with ULTC in the first-ever 13 patients with recurrent monomorphic ventricular tachycardias (VTs) of both ischemic cardiomyopathy and nonischemic etiologies enrolled in the CryoCure-VT (Cryoablation for Monomorphic Ventricular Tachycardia; NCT04893317) clinical trial. After an average of 9.6 ± 4.6 endocardial ULTC lesions per patient, no clinical ventricular tachycardias were inducible in 91% of patients. Two procedure-related serious adverse events recorded in 2 patients resolved post-procedurally without clinical sequelae. Further investigation of both acute and chronic outcomes is warranted and ongoing.
Adagio Medical Inc Laguna Hills California USA
Cardiovascular Center OLV Hospital Aalst Belgium
McGill University Montreal Quebec Canada
Mount Sinai Hospital New York New York USA
Na Homolce Hospital Prague Czech Republic
Citace poskytuje Crossref.org
ClinicalTrials.gov
NCT04893317
